Monash University researchers are developing a novel treatment for pulmonary arterial hypertension (PAH), with crucial support from @BioCurate's Proof of Concept Fund. The team aims to create a disease-modifying therapy for this progressive, incurable condition affecting mainly women. @MonashUni@MIPS_Australia Full story ๐https://t.co/84KeUATYVd
And the exciting part ๐
Oral presentation winners:
@KhabibHamizan #1 student oral p
@ChloeLi595 #2 student oral p
@BhavanaNayer #1 postdoc oral p
Kristy Swiderski #2 postdoc oral p
@DaleFTaylor people's choice
Final program for the #I2T2024 symposium includes: ๐ Invited speakers from across the Melbourne biotech sector
๐ Updates from past MTx pitch competition winners
๐๏ธExpert panel on research commercialisation โ sponsored by @BioCurate
https://t.co/J9G5hxNSpc
๐ A huge thank you to everyone who joined us at @AusBiotech 2024!
We celebrated collaboration and innovationโkey to @BioCurate's mission of translating exceptional research into impactful therapies. Key highlights include engaging discussions and networking with industry leaders.
We're keeping the momentum going with Dr Eric Hayes attending BioEurope in Stockholm 4-6 Nov. Stay tuned for more!
#AusBio2024 #BioCurate #BiotechInnovation @VicGovAu
Just wrapped up an insightful panel on 'Considerations when investing in early-stage university spin-outs' at #AusBio2024! ๐
Dr Kathy Nielsen @BioCurate, shared expertise alongside representatives from Brandon Capital, @MonashUni, @UniseedFund and SYNthesis BioVentures.
Exciting times ahead #AusBio24! #BioInnovation #UniversitySpinouts @VicGovAu@AusBiotech
๐จ Attention #AusBio2024 attendees! ๐จ
Don't miss out on the "Considerations when investing in early-stage university spin-outs" panel today at 2:20 PM - 3:05 PM! ๐
Our very own Dr Kathy Nielsen, CEO at BioCurate, will be sharing her expertise alongside:
Dr Michael Bettess (@mbettess11, Brandon Capital), Dr Aoife Cullen (Monash Innovation), Dr John Kurek (@UniseedFund, Chair), Dr Amir Zalcenstein (SYNthesis BioVentures)
This panel will explore the key elements of successful investing in early-stage university spin-outs, from pipeline potential to managing expectations. ๐ก
๐โโ๏ธ๐โโ๏ธ #BioTech #Investment #Innovation @VicGovAu
#AusBio2024 is well underway! Donโt forget to visit BioCurate at the @VicGovAu Pavilion booth #4.
We look forward to forming new connections with the sector. Stay tuned as weโll be tweeting throughout the conference.
@AusBiotech
#AusBio2024 has officially kicked off today! Don't miss the opportunity to visit us at the @VicGov booth #4. Our team is also available to connect through the AusPartnering program.
Attending:
Dr Kathy Nielsen, CEO
Dr Francis Kirby, Partnerships and Strategy Manager, Dr Frederico Calhabeu, Director of Cell and Gene Therapies,
Dr Tifelle Reisinger, Associate Director, Medicinal Chemistry Discovery and Stakeholder Management
Don't miss Dr Kathy Nielsen on the 'Considerations when investing in early-stage university spin-outs' panel:
๐ Thursday, Oct 31
โฐ 2:20-3:05 PM
@VicGovAu@AusBiotech #AusBio2024
We're grateful to the dedicated team working on this partnership, including:
L-R: Dr Belinda Huff, Dr Andrew Harvey, Dr Matthew McLachlan, Dr Malika Kumarasiri, Dr Eric Hayes, Dr Nick Matovic, Dr Brian Dymock, Dr Julia Beveridge
@BioCurate#UniQuest#QEDDI
BioCurate is excited to announce a new partnership with UniQuestโs #QEDDI, with the aim to develop a new effective treatment for neuropathic pain with potential to become a safe alternative to opioids.
Read more via: https://t.co/b4GM2cqvis
#QEDDI#UniQuest#drugdiscovery #collaboration
โThere is so much need for new treatments and pooling resources and expertise through early-stage partnerships such as this one between BioCurate and #QEDDI is vital to success.โ - Dr Kathy Nielsen, CEO of @BioCurate#UniQuest#drugdiscovery#smallmolecules, #biomedicalresearch, #collaboration, #drugtranslation
BioCurate is excited to announce a new partnership with UniQuestโs #QEDDI, with the aim to develop a new effective treatment for neuropathic pain with potential to become a safe alternative to opioids.
Read more via: https://t.co/b4GM2cqvis
#QEDDI#UniQuest#drugdiscovery #collaboration
Connecting capital with health innovation at #AusBioInvest2024!
BioCurate CEO Dr Kathy Nielsen joins other industry leaders today for ground-breaking discussions on health innovation and investment opportunities in Australia's thriving biotech sector.
Thanks to Host State Partner @VicGovAu for supporting this premier event!
#AusBio2024
Dr Kathy Nielsen will also join other industry leaders #AusBiotechInvest2024 for groundbreaking discussions on health innovation and investment opportunities in Australia's thriving biotech sector ๐ Tuesday, 29th October 2024 ๐งฌ๐ฌ #AusBio2024@VicGovAu
Excited to announce BioCurate will be at AusBiotech 2024 #AusBio2024 in Melbourne, ๐ Oct 30-Nov 1! Join us at the Melbourne Convention & Exhibition Centre for cutting-edge biotech discussions, networking, and exploring innovations in life sciences. Let's shape the future of Australian biotech together! ๐งฌ๐ฌ #Biotech @VicGovAu
Visit us at the @VicGovAu booth #4. Dr Kathy Nielsen, Dr Francis Kirby, Dr Frederico Calhabeu and Dr Tifelle Reisinger will be in attendance. Kathy will be participating in a panel discussing investing in university spin-outs, ๐ Oct 31, โฐ2:20 PM.๐งฌ๐ฌ #AusBio2024
Excited to be part of the team led by @helenaqcx developing a novel treatment for pulmonary arterial hypertension (PAH) here at @MIPS_Australia. Even more excited to be collaborating with and supported by @BioCurate in this goal. @MIPS_DDB@MonashVHI@OzCvA
This collaboration showcases the power of academia-industry partnerships in advancing life-changing therapies. We're excited to see how this project develops and its potential impact on #PAH patients' lives. #MedicalResearch#DrugDiscovery#Innovation#BioCurate
Monash University researchers are developing a novel treatment for pulmonary arterial hypertension (PAH), with crucial support from @BioCurate's Proof of Concept Fund. The team aims to create a disease-modifying therapy for this progressive, incurable condition affecting mainly women. @MonashUni@MIPS_Australia Full story ๐https://t.co/84KeUATYVd
The multidisciplinary team includes Prof @rebeccahritchie , Prof Paul Stupple, Dr @laurentmay, Dr Kieran Stockton, Dr Katie Leach and Julian Vultaggio. Collaborations with @MonashHealth and @AlfredHealth clinicians ensure alignment with patient needs. "We all have the same alignment of goals and mission โ delivering a disease-modifying therapeutic for this devastating disease."